

## **Oncology Based In-Vivo CRO Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028**

Market Report | 2023-05-29 | 142 pages | IMARC Group

### **AVAILABLE LICENSES:**

- Electronic (PDF) Single User \$2499.00
- Five User Licence \$3499.00
- Enterprisewide License \$4499.00

### **Report description:**

Market Overview:

The global oncology based in-vivo CRO market size reached US\$ 1.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US\$ 1.8 Billion by 2028, exhibiting a growth rate (CAGR) of 7.65% during 2023-2028.

Oncology refers to a branch of medicine that studies, diagnoses, and treats cancer using biopsy, endoscopy, X-ray, computed tomography (CT) scanning, magnetic resonance imaging (MRI), positron emission tomography (PET) scanning, and ultrasound. It offers hormonal therapy, immunotherapy, radiotherapy, and oral therapies to patients for tolerating and easing the side effects of cancer. At present, there is a rise in the demand for oncology based in-vivo CRO across the globe due to the development of several investigational compounds by contract research organizations (CROs) for treating cancer.

Oncology Based In-Vivo CRO Market Trends:

The growing prevalence of cancer around the world represents one of the key factors driving the market. Moreover, governments of several countries across the globe are extensively investing in research and development (R&D) activities. This, along with the rising expertise in cancer treatment by contract research organizations (CROs), is propelling the growth of the market. In addition, there is an increase in the innovation of genetic engineering for manipulating deoxyribonucleic acid (DNA) and altering the characteristics of organisms. This, coupled with the growing focus on oncogene study to regulate proliferation, growth, and differentiation of cells, is positively influencing the market. Besides this, the wide availability of medicines, along with the expanding healthcare industry, is catalyzing the demand for oncology based in-vivo CRO worldwide. Apart from this, the cost-efficiency offered by contract research organizations (CROs) compared to an in-house study is offering lucrative growth opportunities to industry investors. Additionally, there is an increase in the adoption of telehealth and virtual clinical trials in the healthcare industry for ensuring the safety of cancer patients. This is projected to bolster the growth of the market.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global oncology based in-vivo CRO market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on indication, model and application.

### Breakup by Indication:

- Blood Cancer
- Solid Tumors
- Others
- 

### Breakup by Model:

- Syngeneic
- Xenograft
- Patient Derived Xenograft (PDX)
- Others
- 

### Breakup by Application:

- Hospitals
- Rehabilitation Centers
- 

### Breakup by Region:

- North America
  - 
  - United States
  - Canada
  -
- Asia-Pacific
  - 
  - China
  - Japan
  - India
  - South Korea
  - Australia
  - Indonesia
  - Others
  -
- Europe
  - 
  - Germany
  - France
  - United Kingdom

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- ☐☐Italy
- ☐☐Spain
- ☐☐Russia
- ☐☐Others
- ☐
- ☐Latin America
- ☐
- ☐☐Brazil
- ☐☐Mexico
- ☐☐Others
- ☐
- ☐Middle East and Africa
- ☐

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Champions Oncology Inc., Charles River Laboratories International Inc., Crown Bioscience Inc., Eurofins Scientific, Evotec SE, ICON Plc, Labcorp Drug Development (Laboratory Corporation of America Holdings), Living Tumor Laboratory, Taconic Biosciences Inc., The Jackson Laboratory, WuXi AppTec and Xentech.

#### Key Questions Answered in This Report:

- What was the size of the global oncology based in-vivo CRO market in 2022?
- What is the expected growth rate of the global oncology based in-vivo CRO market during 2023-2028?
- What are the key factors driving the global oncology based in-vivo CRO market?
- What has been the impact of COVID-19 on the global oncology based in-vivo CRO market?
- What is the breakup of the global oncology based in-vivo CRO market based on the indication?
- What is the breakup of the global oncology based in-vivo CRO market based on the model?
- What are the key regions in the global oncology based in-vivo CRO market?
- Who are the key players/companies in the global oncology based in-vivo CRO market?

#### Table of Contents:

- 1 Preface
- 2 Scope and Methodology
  - 2.1 Objectives of the Study
  - 2.2 Stakeholders
  - 2.3 Data Sources
    - 2.3.1 Primary Sources
    - 2.3.2 Secondary Sources
  - 2.4 Market Estimation
    - 2.4.1 Bottom-Up Approach
    - 2.4.2 Top-Down Approach
  - 2.5 Forecasting Methodology
- 3 Executive Summary
- 4 Introduction
  - 4.1 Overview

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 4.2 Key Industry Trends
- 5 Global Oncology Based In-Vivo CRO Market
  - 5.1 Market Overview
  - 5.2 Market Performance
  - 5.3 Impact of COVID-19
  - 5.4 Market Forecast
- 6 Market Breakup by Indication
  - 6.1 Blood Cancer
    - 6.1.1 Market Trends
    - 6.1.2 Market Forecast
  - 6.2 Solid Tumors
    - 6.2.1 Market Trends
    - 6.2.2 Market Forecast
  - 6.3 Others
    - 6.3.1 Market Trends
    - 6.3.2 Market Forecast
- 7 Market Breakup by Model
  - 7.1 Syngeneic
    - 7.1.1 Market Trends
    - 7.1.2 Market Forecast
  - 7.2 Xenograft
    - 7.2.1 Market Trends
    - 7.2.2 Market Forecast
  - 7.3 Patient Derived Xenograft (PDX)
    - 7.3.1 Market Trends
    - 7.3.2 Market Forecast
  - 7.4 Others
    - 7.4.1 Market Trends
    - 7.4.2 Market Forecast
- 8 Market Breakup by Application
  - 8.1 Hospitals
    - 8.1.1 Market Trends
    - 8.1.2 Market Forecast
  - 8.2 Rehabilitation Centers
    - 8.2.1 Market Trends
    - 8.2.2 Market Forecast
- 9 Market Breakup by Region
  - 9.1 North America
    - 9.1.1 United States
      - 9.1.1.1 Market Trends
      - 9.1.1.2 Market Forecast
    - 9.1.2 Canada
      - 9.1.2.1 Market Trends
      - 9.1.2.2 Market Forecast
  - 9.2 Asia-Pacific
    - 9.2.1 China
      - 9.2.1.1 Market Trends

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
- 9.3 Europe
  - 9.3.1 Germany
    - 9.3.1.1 Market Trends
    - 9.3.1.2 Market Forecast
  - 9.3.2 France
    - 9.3.2.1 Market Trends
    - 9.3.2.2 Market Forecast
  - 9.3.3 United Kingdom
    - 9.3.3.1 Market Trends
    - 9.3.3.2 Market Forecast
  - 9.3.4 Italy
    - 9.3.4.1 Market Trends
    - 9.3.4.2 Market Forecast
  - 9.3.5 Spain
    - 9.3.5.1 Market Trends
    - 9.3.5.2 Market Forecast
  - 9.3.6 Russia
    - 9.3.6.1 Market Trends
    - 9.3.6.2 Market Forecast
  - 9.3.7 Others
    - 9.3.7.1 Market Trends
    - 9.3.7.2 Market Forecast
- 9.4 Latin America
  - 9.4.1 Brazil
    - 9.4.1.1 Market Trends
    - 9.4.1.2 Market Forecast
  - 9.4.2 Mexico
    - 9.4.2.1 Market Trends

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
  - 9.5.1 Market Trends
  - 9.5.2 Market Breakup by Country
  - 9.5.3 Market Forecast
- 10 SWOT Analysis
  - 10.1 Overview
  - 10.2 Strengths
  - 10.3 Weaknesses
  - 10.4 Opportunities
  - 10.5 Threats
- 11 Value Chain Analysis
- 12 Porters Five Forces Analysis
  - 12.1 Overview
  - 12.2 Bargaining Power of Buyers
  - 12.3 Bargaining Power of Suppliers
  - 12.4 Degree of Competition
  - 12.5 Threat of New Entrants
  - 12.6 Threat of Substitutes
- 13 Price Analysis
- 14 Competitive Landscape
  - 14.1 Market Structure
  - 14.2 Key Players
  - 14.3 Profiles of Key Players
    - 14.3.1 Champions Oncology Inc.
      - 14.3.1.1 Company Overview
      - 14.3.1.2 Product Portfolio
      - 14.3.1.3 Financials
    - 14.3.2 Charles River Laboratories International Inc.
      - 14.3.2.1 Company Overview
      - 14.3.2.2 Product Portfolio
      - 14.3.2.3 Financials
      - 14.3.2.4 SWOT Analysis
    - 14.3.3 Crown Bioscience Inc.
      - 14.3.3.1 Company Overview
      - 14.3.3.2 Product Portfolio
    - 14.3.4 Eurofins Scientific
      - 14.3.4.1 Company Overview
      - 14.3.4.2 Product Portfolio
      - 14.3.4.3 Financials
      - 14.3.4.4 SWOT Analysis
    - 14.3.5 Evotec SE
      - 14.3.5.1 Company Overview
      - 14.3.5.2 Product Portfolio

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 ICON Plc
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
  - 14.3.6.3 Financials
  - 14.3.6.4 SWOT Analysis
- 14.3.7 Labcorp Drug Development (Laboratory Corporation of America Holdings)
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
  - 14.3.7.3 SWOT Analysis
- 14.3.8 Living Tumor Laboratory
  - 14.3.8.1 Company Overview
  - 14.3.8.2 Product Portfolio
- 14.3.9 Taconic Biosciences Inc.
  - 14.3.9.1 Company Overview
  - 14.3.9.2 Product Portfolio
- 14.3.10 The Jackson Laboratory
  - 14.3.10.1 Company Overview
  - 14.3.10.2 Product Portfolio
- 14.3.11 WuXi AppTec
  - 14.3.11.1 Company Overview
  - 14.3.11.2 Product Portfolio
  - 14.3.11.3 Financials
- 14.3.12 Xentech
  - 14.3.12.1 Company Overview
  - 14.3.12.2 Product Portfolio

## **Oncology Based In-Vivo CRO Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028**

Market Report | 2023-05-29 | 142 pages | IMARC Group

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

### **ORDER FORM:**

Select license	License	Price
	Electronic (PDF) Single User	\$2499.00
	Five User Licence	\$3499.00
	Enterprisewide License	\$4499.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-25"/>
		Signature	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)  
[www.scotts-international.com](http://www.scotts-international.com)